Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Scancell Holdings plc (SCLP.L)
Oxford, GB
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The company's pipeline features several promising candidates, including SCIB1, currently in Phase II clinical trials for metastatic melanoma; SCIB2, aimed at non-small cell lung cancer; and Modi-1, which is undergoing Phase I/II studies for various indications such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, Scancell is advancing Modi-2, a therapeutic agent specifically designed to target homocitrullinated cancer antigens. Its development efforts also encompass SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine engineered to provide protection against the SARS-CoV-2 virus. Founded in 1997, Scancell Holdings plc is headquartered in Oxford, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.45% | +8.64% | +70.71% | +78.36% | +150.26% | +141.41% | +139.00% | +59.44% | +20.77% | +26.46% | +194.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-85.3% Q4'25: -106.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-226.6%
-
EBIT margin Biotechnology: +0.0%-288.4%
-
ROIC Biotechnology: -16.1%— Q4'25: +2,574.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+12.5% Q4'25: +46.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.28× Q4'25: -0.74× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Apr 2023 actual |
Apr 2024 actual |
Apr 2025 actual |
Apr 2026 2 Rev. Ana. 2 EPS Ana. |
Apr 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
5.27M
est: 3.52M (+49.6%)
|
—
est: 2.65M (-100.0%)
|
4.71M
est: 5.65M (-16.6%)
|
1.25M
1.25M – 1.25M
-77.9% YoY
|
1.20M
1.20M – 1.20M
-4.0% YoY
|
| EBITDA |
-12.19M
est: 704.7K (-1,829.3%)
|
-7.06M
est: 530.0K (-1,432.5%)
|
-12.71M
est: 1.13M (-1,224.5%)
|
250.0K
250.0K – 250.0K
-77.9% YoY
|
240.0K
240.0K – 240.0K
-4.0% YoY
|
| EBIT |
-13.09M
est: 704.7K (-1,957.3%)
|
-8.03M
est: 530.0K (-1,614.7%)
|
-13.59M
est: 1.13M (-1,302.3%)
|
250.0K
250.0K – 250.0K
-77.9% YoY
|
240.0K
240.0K – 240.0K
-4.0% YoY
|
| Net Income |
-11.94M
est: -20.38M (+41.4%)
|
-5.86M
est: -23.36M (+74.9%)
|
-12.27M
est: -12.27M (+0.0%)
|
-6.88M
-9.77M – -3.98M
+44.0% YoY
|
-14.73M
-20.73M – -8.73M
-114.2% YoY
|
| SGA |
5.02M
est: 3.37M (+49.0%)
|
4.43M
est: 2.53M (+74.8%)
|
3.91M
est: 5.40M (-27.7%)
|
1.20M
1.20M – 1.20M
-77.9% YoY
|
1.15M
1.15M – 1.15M
-4.0% YoY
|
| EPS |
-0.01
est: -0.02 (+28.0%)
|
-0.01
est: -0.03 (+73.3%)
|
-0.01
est: -0.01 (-10.8%)
|
-0.01
-0.01 – 0.00
+38.8% YoY
|
-0.02
-0.02 – -0.01
-118.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Phillip John L'Huillier | Chief Executive Officer & Director | 392.0K | — |
| Lindy Gillian Durrant | Chief Scientific Officer, Director & Founder | 386.8K | — |
| Sathijeevan Nirmalananthan | Chief Financial Officer, Company Secretary & Director | 267.8K | male |
| Mandeep Sehmi | Head of Business Development | — | — |
| Nermeen Varawalla DPHIL | Chief Medical Officer | — | — |
| Philip Angell-Manning | Head of CMC | — | male |
| Samantha Paston | Head of Translational Research | — | — |
| Alex Hayward | Finance Director & Company Secretary | — | male |
| Shamim Kazmi Stokes | Head of Programme Management | — | — |
| Callum Scotthasbeen | Senior Vice President of Development | — | — |
| David Schilansky | Interim Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SCLP.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
